Evidence map›Paper›PMID 42013167›Full record

ArticlePLoS pathogens2026

Broadly conserved protective epitopes on the lyme disease vaccine antigen, OspA.

Graham G Willsey, Michael J Rudolph, Carol Lyn Piazza, Yang Chen, Grace Freeman-Gallant, Lisa A Cavacini, David J Vance, Nicholas J Mantis

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. OspA antibodies inhibit theInfection and immunity · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Graham G WillseyDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.
Michael J RudolphNew York Structural Biology Center, New York, New York, United States of America.
Carol Lyn PiazzaDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.
Yang ChenNew York Structural Biology Center, New York, New York, United States of America.
Grace Freeman-GallantDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.
Lisa A CavaciniDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
David J VanceDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.
Nicholas J MantisDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.ORCID https://orcid.org/0000-0002-5083-8640

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lyme disease, caused by the spirochete, Borrelia burgdorferi sensu latu (Bbsl), is a tickborne infection of increasing incidence in North America, Europe and Asia. While vaccines based on Outer surface protein A (OspA) have proven highly efficacious at blocking Bbsl tick-to-human transmission, the high degree of antigenic variability among the major OspA serotypes (ST) has made the development of a broadly cross protective vaccine difficult. Recent profiling of protective human monoclonal antibodies (mAbs) has suggested the existence of conserved epitopes situated within OspA's central β-sheet (CBS), although direct comparisons of cross-serotype functionality has been hindered by biological differences among the major Bbsl genospecies. To address these issues, we developed a panel of isogenic B. burgdorferi reporter strains expressing the seven major OspA serotypes (ST1-7) and probed them with CBS-targeting mAbs to evaluate their complement-dependent borreliacidal activity. The mAbs segregated into three distinct classes: class 1 mAbs exhibited potent killing against all seven OspA serotypes, while classes 2 and 3 had restricted or no activity against two of the seven serotypes. Structural analysis of Fabs derived from each class of mAbs in complex with OspA ST1 showed that they target overlapping epitopes spanning β-strands 6-10 and involve contact with largely invariant residues. Further analysis of B. burgdorferi reporter strains expressing OspA variants from 17 additional Bbsl genospecies identified Lys-107 as a determinant of susceptibility for nearly all CBS mAbs. Taken together, these findings raise the prospect of structure-based design of a broadly protective monovalent Lyme disease vaccine.

Indexed as

Antigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferiEpitopesLipoproteinsLyme DiseaseLyme Disease VaccinesAnimalsAntibodies, BacterialAntibodies, MonoclonalAntigens, BacterialHumansAntibodies, BacterialAntibodies, MonoclonalAntigens, BacterialAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesEpitopesLipoproteinsLyme Disease VaccinesOspA protein

Identifiers

PMID42013167
PMCPMC13138739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.